Open Access

Increased mortality in the A/A genotype of the SNP rs28372698 of interleukin 32

  • Authors:
    • Urban Alehagen
    • Levar Shamoun
    • Jan Ingvar Dimberg
    • Dick Wågsäter
  • View Affiliations

  • Published online on: December 7, 2020     https://doi.org/10.3892/etm.2020.9559
  • Article Number: 127
  • Copyright: © Alehagen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

One of the major causes of mortality in the western hemisphere is cardiovascular disease. Therefore, a variety of markers to identify those at risk are required. Interleukin‑32 (IL‑32) is a cytokine that is associated with inflammation. The aim of the current study was to investigate variations in single nucleotide polymorphisms (SNPs) of IL‑32 and plasma expression, and their associations with mortality. A population of 486 elderly community‑living persons were evaluated. The participants were followed for 7.1 years and underwent a clinical examination and blood sampling. SNP analyses of IL‑32 rs28372698 using allelic discrimination and plasma measurement of IL‑32, using ELISA, were performed. During the follow‑up period, 140 (28.8%) all‑cause and 87 (17.9%) cardiovascular deaths were registered. No significant difference between mortality and plasma concentration of IL‑32 was observed. The A/A genotype group exhibited significantly higher all‑cause mortality (P=0.036), and an almost two‑fold increased risk in a multivariate Cox regression model for all‑cause and cardiovascular mortality. A highly significant difference in all‑cause and cardiovascular mortality between the A/A and the T/T groups was demonstrated (P=0.015 resp. P=0.014). In the present study, the cytokine IL‑32 was demonstrated to have prognostic information, with an increased risk of all‑cause and cardiovascular mortality for those with the A/A genotype rs28372698 of IL‑32. The A/A genotype could therefore be regarded as a possible biomarker for mortality risk that may be used to offer optimized cardiovascular patient handling in the future. However, the present study sample was small, and the results should be regarded as hypothesis‑generating.
View Figures
View References

Related Articles

Journal Cover

February-2021
Volume 21 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Alehagen U, Shamoun L, Dimberg JI and Wågsäter D: Increased mortality in the A/A genotype of the SNP rs28372698 of interleukin 32. Exp Ther Med 21: 127, 2021
APA
Alehagen, U., Shamoun, L., Dimberg, J.I., & Wågsäter, D. (2021). Increased mortality in the A/A genotype of the SNP rs28372698 of interleukin 32. Experimental and Therapeutic Medicine, 21, 127. https://doi.org/10.3892/etm.2020.9559
MLA
Alehagen, U., Shamoun, L., Dimberg, J. I., Wågsäter, D."Increased mortality in the A/A genotype of the SNP rs28372698 of interleukin 32". Experimental and Therapeutic Medicine 21.2 (2021): 127.
Chicago
Alehagen, U., Shamoun, L., Dimberg, J. I., Wågsäter, D."Increased mortality in the A/A genotype of the SNP rs28372698 of interleukin 32". Experimental and Therapeutic Medicine 21, no. 2 (2021): 127. https://doi.org/10.3892/etm.2020.9559